EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intravitreal implant for intravitreal injection for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye; and DEXYCU, a dexamethasone intraocular suspension, for the treatment of post-operative ocular inflammation, including treatment following cataract surgery. It is also developing EYP-1901, a twice-yearly bioerodible formulation of tyrosine kinase inhibitor for the treatment of wet age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion; and YUTIQ50 for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. The company has strategic collaborations with Alimera Sciences, Inc., Bausch & Lomb, OncoSil Medical UK Limited, Ocumension Therapeutics, and Equinox Science, LLC. It also has a commercial alliance with ImprimisRx PA, Inc. for the joint promotion of DEXYCU for the treatment of post-operative inflammation following ocular surgery. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.

EyePoint Pharmaceuticals, Inc.

SERI Lugano is involved in research and innovation in vision, focusing on advanced ophthalmic treatments and therapies for various eye conditions.

SERI Lugano

Vision Biotechnology specializes in developing and manufacturing diagnostic test kits for healthcare professionals to accurately diagnose various diseases. The company incorporates the latest advancements in biotechnology into its products, self-described as elevating healthcare through innovative testing solutions.

Vision Biotechnology

Dry Eye Centre specializes in the analysis and treatment of mild to severe dry eyes, self-described as the first clinic in the UK dedicated solely to this.

Dry Eye Centre

DEXYCU® (dexamethasone intraocular suspension)

YUTIQ® (fluocinolone acetonide intravitreal implant) 0.18 mg

Life at EyePoint Pharma

EyePoint Pharmaceuticals (Nasdaq: EYPT) is a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders. The Company's pipeline leverages its proprietary Durasert® technology for sustained intraocular drug delivery including EYP-1901, a potential six-month intravitreal anti-VEGF treatment initially targeting wet age-related macular degeneration. Durasert’s proven intravitreal drug delivery platform has been safely administered to thousands of patients' eyes across four U.S. FDA-approved products, including YUTIQ® for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye, which is currently marketed by the Company. EyePoint Pharmaceuticals is headquartered in Watertown, Massachusetts.

Metric
Company Name	EyePoint Pharmaceuticals, Inc.	SERI Lugano	Vision Biotechnology	Dry Eye Centre
Symbol	EYPT
MSH ID	COM:EYEPOINTPHARMA	CH:SERI-LUGANO	COM:VISIONBIOTECHNOLOGY	UK:CO:DRYEYECENTRE
Market	STOCKS	PRIVATE	PRIVATE	PRIVATE
Sector	Healthcare	Healthcare & Health Services	Healthcare & Health Services	Healthcare & Health Services
Industry	Biotechnology	Medical & Healthcare	Biotechnology	Medical Services
Country	US	CH	US	GB
Stage
Employee Count	121
Website	eyepointpharma.com	seri-lugano.ch	visionbiotechnology.com	dryeyecentre.co.uk
LinkedIn	eyepointpharmaceuticals	seri-lugano	visionbiotechnolgy
Founders

Metric
Market Cap	452.61M
Enterprise Value
Monthly Web Traffic	5.44K	434
Web Traffic Growth	0.08	1.39
Valuation
Raised Capital

Metric
Revenue	46.02M
Revenue (LTM)
Revenue (NTM)
Gross Profit	41.39M
EBITDA	-73.20M
Operating Income	-73.66M
Net Income	-70.80M
EPS	-1.82
Diluted EPS	-1.82
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.91
Operating Profit Margin	-1.63
EBITDA Margin	-1.59
Net Profit Margin	-1.55
Return on Equity	-0.43
Return on Assets	-0.20
Return on Capital Employed	-0.26

COM:EYEPOINTPHARMA

EyePoint Pharmaceuticals

Last Close

8.35

22/11 21:00

Market Cap

452.61M

Beta: -

Volume Today

1.10M

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-8.81
P/B Ratio	18.23
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	26.82
EV Multiple	-4.96

Metric
Days Sales Outstanding	4.15
Days Payables Outstanding	496.41
Days Inventory Outstanding	327.05
Operating Cycle	349.05
Cash Conversion Cycle	-195.03
Asset Turnover	0.27

Metric
Operating Cash Flow	1.88M
Free Cash Flow	-1.61M
Cash Flow to Debt	1.48
Operating Cash Flow/Sales	0.65
Free Cash Flow Yield	0.03

Metric
Cash & Equivalents	281.26M
Accounts Receivable	14.43M
Inventory	3.91M
Goodwill
Debt to Capitalization	0.24
Debt to Assets	0.12
Current Ratio	2.35
Quick Ratio	5.25

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.19
R&D to Revenue	1.46
SG&A to Revenue	0.88